Shurell-Linehan E, et al. - In order to assess the role of neoadjuvant therapy in malignant peripheral nerve sheath tumors (MPNSTs), researchers reviewed 88 patients (16 years of age and older) with primary localized MPNST who underwent surgical treatment between 1974 and 2012, for clinicopathologic and treatment variables predictive of disease-specific survival (DSS) and disease-free survival. Neoadjuvant chemotherapy was provided to 38 (43%) patients who also had tissue available for analysis. Twenty-five patients (68%) received neoadjuvant radiation. Outcomes revealed continuously debated impact of neoadjuvant chemotherapy on the outcome of primary localized MPNST patients. However, there was an association of pathologic response to therapy with a significant improvement in DSS.